1. Home
  2. NKGN vs GOEV Comparison

NKGN vs GOEV Comparison

Compare NKGN & GOEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKGN
  • GOEV
  • Stock Information
  • Founded
  • NKGN 2017
  • GOEV 2017
  • Country
  • NKGN United States
  • GOEV United States
  • Employees
  • NKGN N/A
  • GOEV N/A
  • Industry
  • NKGN Biotechnology: Biological Products (No Diagnostic Substances)
  • GOEV
  • Sector
  • NKGN Health Care
  • GOEV
  • Exchange
  • NKGN Nasdaq
  • GOEV Nasdaq
  • Market Cap
  • NKGN 22.6M
  • GOEV 19.6M
  • IPO Year
  • NKGN N/A
  • GOEV N/A
  • Fundamental
  • Price
  • NKGN $0.51
  • GOEV $0.37
  • Analyst Decision
  • NKGN
  • GOEV Buy
  • Analyst Count
  • NKGN 0
  • GOEV 6
  • Target Price
  • NKGN N/A
  • GOEV $103.10
  • AVG Volume (30 Days)
  • NKGN 387.8K
  • GOEV 5.3M
  • Earning Date
  • NKGN 01-28-2025
  • GOEV 11-13-2024
  • Dividend Yield
  • NKGN N/A
  • GOEV N/A
  • EPS Growth
  • NKGN N/A
  • GOEV N/A
  • EPS
  • NKGN N/A
  • GOEV N/A
  • Revenue
  • NKGN N/A
  • GOEV $1,864,000.00
  • Revenue This Year
  • NKGN N/A
  • GOEV $2,927.65
  • Revenue Next Year
  • NKGN N/A
  • GOEV $922.67
  • P/E Ratio
  • NKGN N/A
  • GOEV N/A
  • Revenue Growth
  • NKGN N/A
  • GOEV 259.15
  • 52 Week Low
  • NKGN $0.20
  • GOEV $0.32
  • 52 Week High
  • NKGN $4.06
  • GOEV $102.12
  • Technical
  • Relative Strength Index (RSI)
  • NKGN 47.58
  • GOEV 22.52
  • Support Level
  • NKGN $0.39
  • GOEV $1.04
  • Resistance Level
  • NKGN $0.53
  • GOEV $1.79
  • Average True Range (ATR)
  • NKGN 0.07
  • GOEV 0.20
  • MACD
  • NKGN -0.02
  • GOEV 0.23
  • Stochastic Oscillator
  • NKGN 31.88
  • GOEV 3.61

About NKGN NKGen Biotech Inc.

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

About GOEV Canoo Inc.

Canoo Inc is a mobility technology company providing with a proprietary modular electric vehicle platform and connected services initially focused on commercial fleet, government and military customers. The Company has developed a breakthrough EV platform that it believes will enable it to rapidly iterate and bring new products, addressing multiple use cases, to market faster than competition and at lower cost.

Share on Social Networks: